CoChat

The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance

Sale, Matthew J., Cook, Simon J. · 2013 · Biochemical Journal

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

Abstract

Tumour cells typically exhibit a G1 cell cycle arrest in response to the MEK1/2 [mitogen-activated protein kinase/ERK (extracellular-signal-regulated kinase) kinase 1/2] inhibitor selumetinib, but do not die, and thus they acquire resistance. In the present study we examined the effect of combining selumetinib with the BH3 [BCL2 (B-cell lymphoma 2) homology domain 3]-mimetic BCL2 inhibitor ABT-263. Although either drug alone caused little tumour cell death, the two agents combined to cause substantial caspase-dependent cell death and inhibit long-term clonogenic survival of colorectal cancer and melanoma cell lines with BRAFV600E or RAS mutations. This cell death absolutely required BAX (BCL2-associated X protein) and was inhibited by RNAi (RNA interference)-mediated knockdown of BIM (BCL2-interacting mediator of cell death) in the BRAFV600E-positive COLO205 cell line. When colorectal cancer cell lines were treated with selumetinib plus ABT-263 we observed a striking reduction in the incidence of cells emerging with acquired resistance to selumetinib. Similar results were observed when we combined ABT-263 with the BRAFV600E-selective inhibitor PLX4720, but only in cells expressing BRAFV600E. Finally, cancer cells in which acquired resistance to selumetinib arises through BRAFV600E amplification remained sensitive to ABT-263, whereas selumetinib-resistant HCT116 cells (KRASG13D amplification) were cross-resistant to ABT-263. Thus the combination of a BCL2 inhibitor and an ERK1/2 pathway inhibitor is synthetic lethal in ERK1/2-addicted tumour cells, delays the onset of acquired resistance and in some cases overcomes acquired resistance to selumetinib.

Overview

Integrity signals

Registry

Crossref · 10.1042/bj20121212

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Cited by

See all 58

Metadata

Authors
Sale, M. J., & Cook, S. J.
Affiliations
Babraham Institute (GB)
Venue
Biochemical Journal
Published
2013-02-15
Volume
450
Issue
2
Pages
285-294
ISSN
  • 0264-6021 (ISSN-L)
  • 1470-8728
OpenAlex
W2316080015
Cited by
58
References
50
Citations by year
2026: 1 · 2024: 1 · 2023: 5 · 2022: 3 · 2021: 5 · 2020: 1 · 2019: 9 · 2018: 4 · 2017: 4 · 2016: 1 · 2015: 11 · 2014: 8 · 2013: 5
FWCI
3.08
Type
journal article
Language
en
Open access
closed
Locations
  • Biochemical Journal (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Cancer Research UK (C488/A14867, 14867)
  • Biotechnology and Biological Sciences Research Council (BB/E02162X/1, BB/F0158521/1, BBS/E/B/000C0419, BBS/E/B/0000H151)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
navitoclax, selumetinib, BH3 mimetics, BCL-2 inhibitor, MEK inhibitors, acquired drug resistance, building information modeling, Bax, caspase-dependent cell death, synthetic lethality, BRAF V600E mutation, RAS mutations, colorectal cancer, melanoma, PLX4720, combination therapy
MeSH terms
Aniline Compounds, Benzimidazoles, Humans, Sulfonamides, Cell Death, Apoptosis, Drug Resistance, Neoplasm, HT29 Cells, MAP Kinase Signaling System, RNA Interference, Cell Line, Tumor, MAP Kinase Kinase 1, MAP Kinase Kinase 2, bcl-2-Associated X Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.